We advised GenFleet on its IPO and HKEX listing

Davis Polk advised GenFleet Therapeutics (Shanghai) Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and its international offering in reliance on Rule 144A / Regulation S. The gross proceeds of the offering were approximately HK$1.82 billion prior to the exercise of the over-allotment option.

GenFleet is a biopharmaceutical company with proven success in developing RAS-pathway targeted therapies. It is focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, registered foreign lawyer Xin (Sheen) Xu and associates Edwin Lee and Michelle Chow. Counsel Alon Gurfinkel and associates Kelli A. Rivers and Ya Sheng Lin provided tax advice. Counsel Sarah E. Kim and associate Saloni Pant provided Investment Company Act advice. Members of the Davis Polk team are based in the Hong Kong, Beijing, London and New York offices.

Copy link to share post